1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Suven Life Sciences Limited

Suven Life Sciences Limited

SUVEN.BO
Suven Life Sciences LimitedIN flagBombay Stock Exchange
328.40
INR
+8.90
- -
73.53BMarket Cap
Suven Life Sciences Limited
SUVEN.BO
(Bombay Stock Exchange)

Recent

price

328.40

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
11.88
16.12
20.35
40.25
39.92
36.16
38.97
44.35
19.97
1.04
0.98
0.88
0.62
0.54
0.31
0.31
0.32
Revenue per Share
0.81
1.13
2.43
11.37
8.33
5.2
6.31
8.95
-1.73
-6.82
-5.22
-9.05
-5.42
-4.82
-7.37
-12.13
-12.42
Basic EPS, GAAP
0.09
0.51
0.84
6.57
1.89
0.7
5.69
2.04
-6.68
-9.92
-7.41
-10.93
-5.45
-3.79
-8.77
-13.47
- -
Free Cash Flow per Basic Share
0.27
0.27
0.32
0.32
2.62
2.88
0.92
1.66
1.67
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.92
0.92
0.92
13.24
20.17
20.54
24.88
31.05
6.17
-0.67
-5.92
-15
-14.35
-19.17
-26.54
1.16
1.19
Book Value per Share
10
10.07
12.19
20.86
43.18
43.07
48.2
55.36
17.31
10.37
7.81
7.12
17.2
12.37
5.03
25.95
26.57
Tangible Book Value per Share
127
127
127
127
130
138
138
138
138
138
138
135
218
218
218
228
223
Basic Weighted Avg Shares
1,504
2,042
2,579
5,103
5,209
4,995
5,382
6,126
2,758
144
135
118
135
117
67
71
71
Sales/Revenue/Turnover
-97.84
8.61
17.57
41.19
28.64
12.08
20.24
28.92
-8.99
-828.1
-616.99
-1,064.46
-974.35
-1,148.52
-2,578.13
-4,077.7
-4,077.7
Operating Margin (%)
79
85
105
115
242
240
276
248
142
40
35
36
58
58
53
56
56
Depreciation Expense
102
144
308
1,442
1,088
718
872
1,237
-239
-942
-722
-1,220
-1,183
-1,051
-1,607
-2,763
-2,763
Net Income, GAAP
- -
- -
6.13
28.89
28.24
26.37
29.16
36.74
15,423.14
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
6.8
7.03
11.96
28.25
20.88
14.38
16.2
20.19
-8.67
-653.62
-535.31
-1,029.99
-873.52
-898.62
-2,415.11
-3,884.13
-3,884.13
Profit Margin (%)
336
42
295
1,255
3,309
3,170
3,731
4,480
2,413
395
868
583
2,405
2,432
520
5,158
5,158
Working Capital
349
550
642
377
594
416
259
22
18
40
27
16
6
- -
- -
- -
- -
LT Debt
1,267
1,275
1,545
2,644
5,637
5,953
6,670
7,674
2,391
1,433
1,080
961
3,753
2,700
1,100
5,914
5,914
Total Equity
- -
- -
18.83
51.79
21.39
6.59
10.9
14.56
728.13
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
31.92
87.95
36.7
20.34
23.02
28.6
-75.48
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
87.98
123.04
264.08
160.58
50.46
26.27
27.79
32.02
-9.3
- -
- -
- -
- -
- -
- -
- -
-951.14
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
- -
- -
167
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
227
- -
264
Market Capitalization
44,560
36,790
29,565

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
2,782
- -
5,467
Cash, Cash Equivalents & STI
2,585
- -
5,218
Accounts Receivable, Net
11
- -
15
Inventories
2
- -
1
Total Current Liabilities
544
- -
309
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
167
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
52.33%
125.95%
437.7%
Free Cash Flow
43.31%
37.23%
60.35%
Net Income, GAAP
39.44%
35.95%
71.91%
Sales/Revenue/Turnover
-18.23%
-9.53%
6.89%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
38
31
25
24
117
2025
10
26
16
15
67
2026
19
9
28
15
71

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.1
-0.58
-1.92
- -
-4.82
2025
-1.29
-2.27
-1.79
-2.02
-7.37
2026
-2.36
-3.48
-4.55
-2.02
-12.13

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Kaken Pharmaceutical Co., Ltd. (4521.T)
Silo Wellness Inc. (SILFF)
EXMceuticals Inc. (EXM.CN)
Solara Active Pharma Sciences Limited (SOLARA.BO)
Marijuana Company of America, Inc. (MCOA)
TSH Biopharm Corporation Limited (8432.TWO)
Business
Suven Life Sciences Limited (SUVEN.BO), founded in 1989 and headquartered in Hyderabad, India, is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics targeting neurodegenerative disorders, particularly in the central nervous system (CNS) space; its core pipeline includes new chemical entities (NCEs) such as SUVN-502 for cognition and neuropsychiatric symptoms in Alzheimer's disease, SUVN-911 (ropanicant) for major depressive disorder with Phase 2B trials initiated, SUVN-D4010 for Alzheimer's cognition, and programs addressing cognitive impairments like amnesia, dementia, narcolepsy, and pain management across a robust portfolio of over 14 molecules; the company operates through its wholly owned U.S. subsidiary Suven Neurosciences Inc. for clinical development from Phase 2 onward and maintains state-of-the-art facilities supporting drug discovery, preclinical and clinical trials, analytical services, and regulatory management for global pharma and biotech clients. Following the 2019-2020 demerger of its Contract Research and Manufacturing Services (CRAMS) business into Suven Pharmaceuticals Limited, Suven Life Sciences streamlined operations to prioritize biopharma innovation; recent advancements encompass the successful completion of Phase 1 trials for multiple candidates, first patient randomization in the Phase 2B trial for ropanicant in 2025, a 2024 licensing agreement with Taro Pharmaceuticals for Malathion lotion, approval of a rights issue in October 2024 to raise up to 4 billion rupees, and ongoing U.S. FDA inspections with acceptance at key units like Pashamylaram. Suven serves pharmaceutical and biotech industries worldwide, with primary operations in India and the United States.